Agios Pharmaceuticals, Inc.
AGIO
$34.41
-$1.09-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.49% | -0.61% | 1,137.97% | -14.69% | -0.66% |
| Total Depreciation and Amortization | -5.19% | -2.57% | -17.13% | -11.84% | -24.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.79% | -49.84% | -3,607.25% | 3.33% | -5.11% |
| Change in Net Operating Assets | -25.94% | -926.09% | 1,778.50% | 164.98% | -12.45% |
| Cash from Operations | -11.64% | -83.71% | -36.62% | -8.75% | -4.92% |
| Capital Expenditure | -443.26% | -313.25% | -13.55% | -5,366.67% | 64.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -73.33% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.07% | -150.33% | 32.90% | -20.63% | 115.51% |
| Cash from Investing | -9.61% | -151.47% | 537.49% | -20.97% | 116.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -72.39% | 471.66% | 40.12% | 363.71% | 137.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -72.39% | 471.66% | 40.12% | 363.71% | 137.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.11% | -843.48% | 928.66% | -76.65% | 187.01% |